1
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
|
2
|
Bruix J and Sherman M; American
Association for the Study of Liver Diseases. Management of
hepatocellular carcinoma: an update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
3
|
Bruix J, Boix L, Sala M and Llovet JM:
Focus on hepatocellular carcinoma. Cancer Cell. 5:215–219. 2004.
View Article : Google Scholar
|
4
|
Bruix J and Sherman M; Practice Guidelines
Committee, American Association for the Study of Liver Diseases.
Management of hepatocellular carcinoma. Hepatology. 42:1208–1236.
2005. View Article : Google Scholar
|
5
|
Paul M, Poyan Mehr A and Kreutz R:
Physiology of local renin-angiotensin systems. Physiol Rev.
86:747–803. 2006. View Article : Google Scholar : PubMed/NCBI
|
6
|
Wang CH, Li F and Takahashi N: The renin
angiotensin system and the metabolic syndrome. Open Hypertens J.
3:1–13. 2010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Tahmasebi M, Barker S, Puddefoot JR and
Vinson GP: Localisation of renin-angiotensin system (RAS)
components in breast. Br J Cancer. 95:67–74. 2006. View Article : Google Scholar : PubMed/NCBI
|
8
|
Jethon A, Pula B, Piotrowska A, et al:
Angiotensin II type 1 receptor (AT-1R) expression correlates with
VEGF-A and VEGF-D expression in invasive ductal breast cancer.
Pathol Oncol Res. 18:867–873. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Deshayes F and Nahmias C: Angiotensin
receptors: a new role in cancer? Trends Endocrinol Metab.
16:293–299. 2005. View Article : Google Scholar : PubMed/NCBI
|
10
|
Kobie JJ, Wu RS, Kurt RA, et al:
Transforming growth factor beta inhibits the antigen-presenting
functions and antitumor activity of dendritic cell vaccines. Cancer
Res. 63:1860–1864. 2003.PubMed/NCBI
|
11
|
Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al:
Inflammation and angiotensin II. Int J Biochem Cell Biol.
35:881–900. 2003. View Article : Google Scholar
|
12
|
Tsutamoto T, Wada A, Maeda K, et al:
Angiotensin II type 1 receptor antagonist decreases plasma levels
of tumor necrosis factor alpha, interleukin-6 and soluble adhesion
molecules in patients with chronic heart failure. J Am Coll
Cardiol. 35:714–721. 2000. View Article : Google Scholar
|
13
|
Kawamata H, Furihata T, Omotehara F, et
al: Identification of genes differentially expressed in a newly
isolated human metastasizing esophageal cancer cell line, T.Tn-AT1,
by cDNA microarray. Cancer Sci. 94:699–706. 2003. View Article : Google Scholar
|
14
|
Wilop S, von Hobe S, Crysandt M, et al:
Impact of angiotensin I converting enzyme inhibitors and
angiotensin II type 1 receptor blockers on survival in patients
with advanced non-small-cell lung cancer undergoing first-line
platinum-based chemotherapy. J Cancer Res Clin Oncol.
135:1429–1435. 2009. View Article : Google Scholar
|
15
|
Huang W, Wu YL, Zhong J, et al:
Angiotensin II type 1 receptor antagonist suppress angiogenesis and
growth of gastric cancer xenografts. Dig Dis Sci. 53:1206–1210.
2008. View Article : Google Scholar : PubMed/NCBI
|
16
|
Huang W, Yu LF, Zhong J, et al:
Angiotensin II type 1 receptor expression in human gastric cancer
and induces MMP2 and MMP9 expression in MKN-28 cells. Dig Dis Sci.
53:163–168. 2008. View Article : Google Scholar : PubMed/NCBI
|
17
|
Inwang ER, Puddefoot JR, Brown CL, et al:
Angiotensin II type 1 receptor expression in human breast tissues.
Br J Cancer. 75:1279–1283. 1997. View Article : Google Scholar : PubMed/NCBI
|
18
|
Chen X, Meng Q, Zhao Y, et al: Angiotensin
II type 1 receptor antagonists inhibit cell proliferation and
angiogenesis in breast cancer. Cancer Lett. 328:318–324. 2013.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Ino K, Shibata K, Kajiyama H, et al:
Angiotensin II type 1 receptor expression in ovarian cancer and its
correlation with tumour angiogenesis and patient survival. Br J
Cancer. 94:552–560. 2006. View Article : Google Scholar : PubMed/NCBI
|
20
|
Tanaka N, Miyajima A, Kosaka T, et al:
Acquired platinum resistance enhances tumour angiogenesis through
angiotensin II type 1 receptor in bladder cancer. Br J Cancer.
105:1331–1337. 2011. View Article : Google Scholar : PubMed/NCBI
|
21
|
Shirotake S, Miyajima A, Kosaka T, et al:
Angiotensin II type 1 receptor expression and microvessel density
in human bladder cancer. Urology. 77:e19–25. 2011. View Article : Google Scholar : PubMed/NCBI
|
22
|
Ohta T, Amaya K, Yi S, et al: Angiotensin
converting enzyme-independent, local angiotensin II-generation in
human pancreatic ductal cancer tissues. Int J Oncol. 23:593–598.
2003.PubMed/NCBI
|
23
|
Gong Q, Davis M, Chipitsyna G, et al:
Blocking angiotensin II type 1 receptor triggers apoptotic cell
death in human pancreatic cancer cells. Pancreas. 39:581–594. 2010.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Uemura H, Ishiguro H, Nakaigawa N, et al:
Angiotensin II receptor blocker shows antiproliferative activity in
prostate cancer cells: a possibility of tyrosine kinase inhibitor
of growth factor. Mol Cancer Ther. 2:1139–1147. 2003.
|
25
|
Guimond MO, Battista MC, Nikjouitavabi F,
et al: Expression and role of the angiotensin II AT2 receptor in
human prostate tissue: in search of a new therapeutic option for
prostate cancer. Prostate. 73:1057–1068. 2013. View Article : Google Scholar : PubMed/NCBI
|
26
|
Hoshino K, Ishiguro H, Teranishi J, et al:
Regulation of androgen receptor expression through angiotensin II
type 1 receptor in prostate cancer cells. Prostate. 71:964–975.
2011. View Article : Google Scholar : PubMed/NCBI
|
27
|
Kosaka T, Miyajima A, Shirotake S, et al:
Phosphorylated Akt up-regulates angiotensin II type-1 receptor
expression in castration resistant prostate cancer. Prostate.
71:1510–1517. 2011.PubMed/NCBI
|
28
|
Di MJ, Wang WX, Lan MY, et al: Expression
and significance of angiotensin II typeI receptor in human
hepatocellular carcinoma. Medical Journal of Wuhan University.
26:235–237. 2005.(In Chinese).
|
29
|
Wu Y, Cahill PA and Sitzmann JV: Decreased
angiotensin II receptors mediate decreased vascular response in
hepatocellular cancer. Ann Surg. 223:225–231. 1996. View Article : Google Scholar : PubMed/NCBI
|
30
|
Edmondson HA and Steiner PE: Primary
carcinoma of the liver: a study of 100 cases among 48,900
necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
|
31
|
Capece D, Fischietti M, Verzella D, et al:
The inflammatory microenvironment in hepatocellular carcinoma: a
pivotal role for tumor-associated macrophages. Biomed Res Int.
2013:1872042013. View Article : Google Scholar : PubMed/NCBI
|
32
|
Holash J, Maisonpierre PC, Compton D, et
al: Vessel cooption, regression, and growth in tumors mediated by
angiopoietins and VEGF. Science. 284:1994–1998. 1999. View Article : Google Scholar : PubMed/NCBI
|
33
|
Li XM, Tang ZY, Qin LX, et al: Serum
vascular endothelial growth factor is a predictor of invasion and
metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res.
18:511–517. 1999.PubMed/NCBI
|
34
|
Fujiyama S, Matsubara H, Nozawa Y, et al:
Angiotensin AT(1) and AT(2) receptors differentially regulate
angiopoietin-2 and vascular endothelial growth factor expression
and angiogenesis by modulating heparin binding-epidermal growth
factor (EGF)-mediated EGF receptor transactivation. Circ Res.
88:22–29. 2001. View Article : Google Scholar
|
35
|
Takeda H and Kondo S: Differences between
squamous cell carcinoma and keratoacanthoma in angiotensin type-1
receptor expression. Am J Pathol. 158:1633–1637. 2001. View Article : Google Scholar : PubMed/NCBI
|
36
|
De Paepe B, Verstraeten VL, De Potter CR,
et al: Growth stimulatory angiotensin II type-1 receptor is
upregulated in breast hyperplasia and in situ carcinoma but not in
invasive carcinoma. Histochem Cell Biol. 116:247–254.
2001.PubMed/NCBI
|